AVITA Medical will hold an investor webinar on May 20, 2026, to discuss its Q1 2026 financial and business results, followed by a Q&A session. On May 21, 2026, the company will host an armchair investor discussion in Melbourne featuring CEO Cary Vance and healthcare investor Michael Woods, focusing on commercial progress and priorities for 2026. Both events aim to update shareholders and prospective investors on AVITA's wound care platform and strategic outlook. Replays will be available on AVITA Medical's website.
Life360's Board of Directors has approved a multi-year share repurchase program worth up to $225 million to reduce dilution from stock-based compensation. The program aims to return value to shareholders and is supported by the company's strong balan...
President Donald Trump secured a major deal with China, where China agreed to purchase at least $17 billion worth of US agricultural products annually until 2028. This agreement was announced after a two-day summit in China, the first by a US preside...
Former President Donald Trump issued a stern warning to Iran, urging swift action in stalled peace negotiations or face severe consequences. He rejected Iran's demand to separate nuclear talks from peace discussions, emphasizing that time is critical...
Design Therapeutics, a clinical-stage biotech company, will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2, a treatment for Friedreich’s ataxia, on May 18, 2026. The company will host a live webcast and conference call to discu...
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
